- Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
- Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
- Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
- Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
- Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
- Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
- Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
More ▼
Key statistics
As of last trade Lisata Therapeutics Inc (8NE:STU) traded at 3.18, -4.79% below its 52-week high of 3.34, set on Jul 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.18 |
---|---|
High | 3.20 |
Low | 3.18 |
Bid | 3.00 |
Offer | 3.28 |
Previous close | 3.18 |
Average volume | 0.00 |
---|---|
Shares outstanding | 8.31m |
Free float | 6.75m |
P/E (TTM) | -- |
Market cap | 29.03m USD |
EPS (TTM) | -2.46 USD |
Data delayed at least 15 minutes, as of Jul 23 2024.
More ▼